(Q39654683)

13 September 2017

1 reference

title

Nonsurgical treatments for skin cancer: retinoids and alpha-interferon (English)

1 reference

13 September 2017

1 reference

1

Lippman SM

1 reference

13 September 2017

Frank L. Meyskens, Jr.

series ordinal

3

object named as

Meyskens FL Jr

1 reference

13 September 2017

Shimm DS

2

1 reference

13 September 2017

publication date

1 August 1988

1 reference

The Journal of dermatologic surgery and oncology

13 September 2017

published in

1 reference

13 September 2017

volume

14

1 reference

13 September 2017

issue

8

1 reference

13 September 2017

page(s)

862-869

1 reference

Identification of a receptor for the morphogen retinoic acid

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Recombinant Leukocyte A Interferon: Pharmacokinetics, Single-Dose Tolerance, and Biologic Effects in Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Metastases in Dermatological Patients With Squamous Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Retardation of experimental oral cancer development by retinyl acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Effect of retinoids on the growth of squamous cell carcinoma of the palate in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Clinical studies of recombinant interferon alfa-2a (Roferon-A) in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Clinical results of leukocyte interferon-induced tumor regression in resistant human metastatic cancer resistant to chemotherapy and/or radiotherapy-pulse therapy schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

Isotretinoin in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4725.1988.TB03590.X

10.1111/J.1524-4725.1988.TB03590.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference